



# P K R JAIN HEALTHCARE INSTITUTE

NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

**A PIONEER DIAGNOSTIC CENTRE**

☎ 0171-2532620, 8222896961

✉ pkrjainhealthcare@gmail.com

**NAME** : Mr. PAWAN KUMAR

**AGE/ GENDER** : 61 YRS/MALE

**COLLECTED BY** :

**REFERRED BY** :

**BARCODE NO.** : 12504001

**CLIENT CODE.** : P.K.R JAIN HEALTHCARE INSTITUTE

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

**PATIENT ID** : 1572070

**REG. NO./LAB NO.** : 122408060004

**REGISTRATION DATE** : 06/Aug/2024 08:41 AM

**COLLECTION DATE** : 06/Aug/2024 08:42AM

**REPORTING DATE** : 06/Aug/2024 01:01PM

Test Name	Value	Unit	Biological Reference interval
-----------	-------	------	-------------------------------

## CLINICAL CHEMISTRY/BIOCHEMISTRY

### LIPID PROFILE : BASIC

CHOLESTEROL TOTAL: SERUM  
by CHOLESTEROL OXIDASE PAP

181.47

mg/dL

OPTIMAL: < 200.0

BORDERLINE HIGH: 200.0 - 239.0

HIGH CHOLESTEROL: > OR = 240.0

TRIGLYCERIDES: SERUM  
by GLYCEROL PHOSPHATE OXIDASE (ENZYMATIC)

403.29<sup>H</sup>

mg/dL

OPTIMAL: < 150.0

BORDERLINE HIGH: 150.0 - 199.0

HIGH: 200.0 - 499.0

VERY HIGH: > OR = 500.0

HDL CHOLESTEROL (DIRECT): SERUM  
by SELECTIVE INHIBITION

29.87<sup>L</sup>

mg/dL

LOW HDL: < 30.0

BORDERLINE HIGH HDL: 30.0 - 60.0

HIGH HDL: > OR = 60.0

LDL CHOLESTEROL: SERUM  
by CALCULATED, SPECTROPHOTOMETRY

NOT CALCULATED

mg/dL

OPTIMAL: < 100.0

ABOVE OPTIMAL: 100.0 - 129.0

BORDERLINE HIGH: 130.0 - 159.0

HIGH: 160.0 - 189.0

VERY HIGH: > OR = 190.0

NON HDL CHOLESTEROL: SERUM  
by CALCULATED, SPECTROPHOTOMETRY

151.6<sup>H</sup>

mg/dL

OPTIMAL: < 130.0

ABOVE OPTIMAL: 130.0 - 159.0

BORDERLINE HIGH: 160.0 - 189.0

HIGH: 190.0 - 219.0

VERY HIGH: > OR = 220.0

VLDL CHOLESTEROL: SERUM  
by CALCULATED, SPECTROPHOTOMETRY

NOT CALCULATED

mg/dL

0.00 - 45.00

TOTAL LIPIDS: SERUM  
by CALCULATED, SPECTROPHOTOMETRY

NOT CALCULATED

mg/dL

350.00 - 700.00

CHOLESTEROL/HDL RATIO: SERUM  
by CALCULATED, SPECTROPHOTOMETRY

6.08<sup>H</sup>

RATIO

LOW RISK: 3.30 - 4.40

AVERAGE RISK: 4.50 - 7.0

MODERATE RISK: 7.10 - 11.0

HIGH RISK: > 11.0

LDL/HDL RATIO: SERUM

NOT CALCULATED

RATIO

LOW RISK: 0.50 - 3.0



DR.VINAY CHOPRA  
CONSULTANT PATHOLOGIST  
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA  
CONSULTANT PATHOLOGIST  
MBBS, MD (PATHOLOGY)





# P K R JAIN HEALTHCARE INSTITUTE

NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

**A PIONEER DIAGNOSTIC CENTRE**

☎ 0171-2532620, 8222896961 ✉ pkrjainhealthcare@gmail.com

NAME	: Mr. PAWAN KUMAR	PATIENT ID	: 1572070
AGE/ GENDER	: 61 YRS/MALE	REG. NO./LAB NO.	: 122408060004
COLLECTED BY	:	REGISTRATION DATE	: 06/Aug/2024 08:41 AM
REFERRED BY	:	COLLECTION DATE	: 06/Aug/2024 08:42AM
BARCODE NO.	: 12504001	REPORTING DATE	: 06/Aug/2024 01:01PM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTITUTE		
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA		

Test Name	Value	Unit	Biological Reference interval
by CALCULATED, SPECTROPHOTOMETRY			MODERATE RISK: 3.10 - 6.0 HIGH RISK: > 6.0
TRIGLYCERIDES/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	13.5 <sup>H</sup>	RATIO	3.00 - 5.00
NOTE 2	WHEN TRIGLYCERIDES VALUE >400 mg/dL THE CALCULATED VALUES OF LDL AND VLDL ARE NOT RELIABLE		

#### INTERPRETATION:

- Measurements in the same patient can show physiological & analytical variations. Three serial samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.
- As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
- Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
- NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogenic lipoproteins such as LDL, VLDL, IDL, Lp(a), Chylomicron remnants) along with LDL-cholesterol as co-primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL & Non HDL.
- Additional testing for Apolipoprotein B, hsCRP, Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement

\*\*\* End Of Report \*\*\*



DR.VINAY CHOPRA  
CONSULTANT PATHOLOGIST  
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA  
CONSULTANT PATHOLOGIST  
MBBS, MD (PATHOLOGY)

